Delighted to have been part of European Crohn’s and Colitis Organization in Berlin, Germany!

We are happy to share that our research study, titled “Patient-reported outcomes in a Greek cross-sectional survey of inflammatory bowel disease patients treated with biologic therapy,” was presented at the 20th Congress of the European Crohn’s and Colitis Organisation (ECCO) in Berlin, Germany.

✅ Our research focuses on patient-reported outcomes (PROs), providing valuable insights into the real-life experiences of Greek IBD patients undergoing biologic therapy.
✅ By capturing patient perspectives, we aim to enhance treatment strategies and improve overall quality of care.
✅ Our study underscores that despite the use of biologic therapies, the disease burden remains high in IBD, with poor quality of life (QoL), increased work impairment, higher rates of depression, and active disease in Greek patients.
✅ Notably, four out of ten patients reported marked dissatisfaction with their treatment.

We are deeply grateful for our collaboration with HELLESCC and its President, whose dedication to advocating for IBD patients has been truly inspiring. This partnership highlights the importance of integrating scientific research with patient-driven initiatives to drive meaningful progress in IBD care.

At Health Through Evidence, we look forward to continuing our research and advancing a future where patient voices shape the evolution of IBD treatment.

Find more about our study :Study link